The Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuropathy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Neuropathy - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuropathy and features dormant and discontinued products.

GlobalData tracks 117 drugs in development for Neuropathy by 96 companies/universities/institutes. The top development phase for Neuropathy is preclinical with 50 drugs in that stage. The Neuropathy pipeline has 109 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Neuropathy pipeline products market are: SwanBio Therapeutics, Praetego and Takeda Pharmaceutical.

The key targets in the Neuropathy pipeline products market include Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), and IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN).

The key mechanisms of action in the Neuropathy pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with six drugs in Phase II. The Neuropathy pipeline products include 15 routes of administration with the top ROA being Oral and 14 key molecule types in the Neuropathy pipeline products market including Small Molecule, and Monoclonal Antibody.

Neuropathy overview

Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions like autoimmune diseases, infections, traumatic injuries, vitamin deficiencies, toxic exposures, or hereditary factors; and idiopathic neuropathy, with an unknown cause. Symptoms of neuropathy can include tingling or numbness in the hands, feet, or other areas;burning or shooting pain; sensitivity to touch; muscle weakness or paralysis; coordination problems or difficulty walking; and changes in sensation, such as temperature sensitivity.

For a complete picture of Neuropathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.